ANTI-CD22 90y-epratuzumab tetraxetan combined with anti-cd20 veltuzumab: A phase I study in patients with relapsed/refractory, aggressive non-hodgkin lymphoma

Thomas E. Witzig, Michael B. Tomblyn, Jamal G. Misleh, Ebenezer A. Kio, Robert M. Sharkey, William A. Wegener, David M. Goldenberg

Research output: Contribution to journal › Article › peer-review

12 Scopus citations

Fingerprint

Dive into the research topics of 'ANTI-CD22 90y-epratuzumab tetraxetan combined with anti-cd20 veltuzumab: A phase I study in patients with relapsed/refractory, aggressive non-hodgkin lymphoma'. Together they form a unique fingerprint.

Medicine & Life Sciences